Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study
References (28)
- et al.
Comparative efficacy and safety of MAOI's versus TCA's in treating depression in the elderly
Biol. Psychiatry
(1986) - et al.
Importance of oxidation polymorphism and levopromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites
Eur. J. Clin. Pharmacol.
(1986) - et al.
The use of rating scales exemplified by a comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale
Acta Psychiatr. Scand.
(1980) - et al.
Quantitative rating of depressive states. Correlation between clinical assessment, self rating scale (Beck's depressive inventory), and objective rati ng scale
Acta Psychiatr. Scand.
(1975) - et al.
The WHO depression scale: relationship to the Newcastle scales
Acta Psychiatr. Scand.
(1980) - et al.
Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-II syndromes
Acta Psychiatr. Scand.
(1986) - Beecham Laboratories (U.S.A.) Data on file, personal...
- et al.
Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
Drugs
(1986) - et al.
Dose-dependent kinetics of imipramine in elderly patients
Psychopharmacology
(1981) - et al.
Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics
Eur. J. Clin. Pharmacol.
(1986)
The diagnosis of depressive syndromes and the prediction of ECT response
Br. J. Psychiatry
A double blind comparison of paroxetine and placebo in the treatment of depressed outpatients
Mianserin and maprotiline as compared to amitriptyline in severe endogenous depression
Pharmacopsychiatry
Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study
Psychopharmacology
Cited by (520)
Clinical predictors of incident somatic morbidity in a sample of depressed patients: A 16–30 years follow-up study
2021, European Journal of PsychiatryGenetic variants in major depressive disorder: From pathophysiology to therapy
2019, Pharmacology and TherapeuticsA quantitative review on outcome-to-antidepressants in melancholic unipolar depression
2018, Psychiatry ResearchCan we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies
2018, European NeuropsychopharmacologyCitation Excerpt :Moreover, MAOI can cause severe hypertensive episodes when associated with tyramine-containing foods. However, despite that the lack of severe side effects and increased treatment compliance, newer drugs did not surpass the efficacy of some TCA, such as chlomipramine (Danish University Antidepressant Group 1986, 1990). Clinical trials in research settings with selected patient populations typically yield response and remission rates of ~60% and ~40%, respectively, with standard antidepressant drugs (Tollefson and Holman, 1994; Stahl, 2000; Thase et al., 2001).
Developments in the field of antidepressants, where do we go now?
2015, European Neuropsychopharmacology
- ∗
participating centers: 1Department of Psychiatry, Odense University, Odense, 2Departments of Psychiatry, Frederiksborg general Hospital, Hillerød, 3Department of psychiatry, Rigshospitalet, University of Copenhagen, 4Departments A and C, Psychiatric University Hospital, Århus, 5Department of Psychiatry, Frederiksberg Hospital, Frederiksberg, 6Department of Psychiatry, Bornholm General Hospital, Rønne, 7Department of Clinical Pharmacology, Odense University, Odense (Demanrk) Participating clinicians: B. Andersen1, K. Brøsen1, P. Christenen1, A. Lolk1, P. kragh-Sørensen1, S. Nielsen1, O.L. Ped 1, P. Rask1, P. bech2, H. Bjerrum2,3, L. Clemmesen2, H. Folker2, L. lauritsen2, D. Loldrup2, O.J. Rafaelsen3, K. Ødum3, U. Bartels4, E.B. Jensen4, N. Nielsen4, N. Reisby4. A. Weeke4, P. Vestergaard4, P. Videbech4, A. Amdisen4, E.M. Andersen5, S. Bøjholm6 Coordination and drug assay; L.F. Gram7, K. Brøsen7, K.B. Nielsen7 Study monitor: L. Rostrup (Ferrosan Ltd.) Steering Committee:L.F. Gram (chairman), P. Bech, P. kragh-Sørensen, O.J. Rafaelsen, N.Reisby, P. Vestergaard